Jiang Min, Hua Zhongyan, Dong Yudi, Liu Zhihui, Thiele Carol J, Li Zhijie
Medical Research Center, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Cellular & Molecular Biology Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Transl Cancer Res. 2018 Dec;7(6):1548-1560. doi: 10.21037/tcr.2018.11.30.
Perifosine, is a third generation alkylphospholipid analog which has promising anti-tumor efficacy in clinical trials of refractory/recurrent neuroblastoma (NB). However, perifosine's mechanism of action remains unclear. Previously, we have shown that perifosine changes global proteome and acetylome profiles in NB.
To obtain a more comprehensive understanding of the perifosine mechanism, we performed a quantitative assessment of the lysine ubiquitylome in SK-N-AS NB cells using SILAC labeling, affinity enrichment and high-resolution liquid chromatography combined with mass spectrometry analysis. To analyse the data of ubiquitylome, we performed enrichment analysis with gene ontology (GO), the Encyclopedia of Genes and Genomes (KEGG) pathway, ubiquitylated lysine motif, protein complex and protein domain. Protein-protein interaction was conducted to explore the crosstalk between ubiquitylome and previous global proteome/acetylome. Co-immunoprecipitation and western blotting were used to validate the results of the ubiquitylome analysis.
Altogether, 3,935 sites and 1,658 proteins were quantified. These quantified ubiquitylated proteins participated in various cellular processes such as binding, catalytic activity, biological regulation, metabolic process and signaling pathways involving non-homologous end-joining, steroid biosynthesis and Ras signaling pathway. Ubiquitylome and proteome presented negative connection. We identified 607 sites which were modified with both ubiquitination and acetylation. We selected 14 proteins carrying differentially quantified lysine ubiquitination and acetylation sites at the threshold of 1.5 folds as potential targets. These proteins were enriched in activities associated with ribosome, cell cycle and metabolism.
Our study extends our understanding of the spectrum of novel targets that are differentially ubiquitinated after perifosine treatment of NB tumor cells.
哌立福新是一种第三代烷基磷脂类似物,在难治性/复发性神经母细胞瘤(NB)的临床试验中具有有前景的抗肿瘤疗效。然而,哌立福新的作用机制仍不清楚。此前,我们已表明哌立福新可改变NB中的整体蛋白质组和乙酰化蛋白质组图谱。
为了更全面地了解哌立福新的作用机制,我们使用稳定同位素标记氨基酸法(SILAC)标记、亲和富集以及高分辨率液相色谱结合质谱分析,对SK-N-AS NB细胞中的赖氨酸泛素化蛋白质组进行了定量评估。为了分析泛素化蛋白质组数据,我们利用基因本体论(GO)、基因与基因组百科全书(KEGG)通路、泛素化赖氨酸基序、蛋白质复合物和蛋白质结构域进行了富集分析。进行蛋白质-蛋白质相互作用分析以探索泛素化蛋白质组与先前的整体蛋白质组/乙酰化蛋白质组之间的相互作用。采用免疫共沉淀和蛋白质印迹法验证泛素化蛋白质组分析结果。
总共定量了3935个位点和1658种蛋白质。这些定量的泛素化蛋白质参与了各种细胞过程,如结合、催化活性、生物调节、代谢过程以及涉及非同源末端连接、类固醇生物合成和Ras信号通路的信号传导途径。泛素化蛋白质组与蛋白质组呈现负相关。我们鉴定出607个同时被泛素化和乙酰化修饰的位点。我们选择了14种在阈值为1.5倍时携带差异定量赖氨酸泛素化和乙酰化位点的蛋白质作为潜在靶点。这些蛋白质富集于与核糖体、细胞周期和代谢相关的活性中。
我们的研究扩展了我们对NB肿瘤细胞经哌立福新处理后差异泛素化的新靶点谱的理解。